A team led by Professor Takuya Takahashi at Yokohama City University in Japan has used PET imaging to show for the first time how ketamine reshapes AMPA receptors — proteins critical for neuron communication — in specific brain regions tied to mood and reward. The study, published March 5 in Molecular Psychiatry, tracked 34 patients with treatment-resistant depression and 49 healthy controls who received intravenous ketamine or placebo over two weeks.

The scans revealed that ketamine triggers region-specific changes in AMPA receptor density: some cortical areas showed increased levels while reward-processing regions like the habenula showed reductions. These shifts correlated directly with symptom improvement, suggesting AMPAR dynamics are the mechanism behind ketamine's rapid antidepressant action.

About 30% of people diagnosed with depression develop treatment-resistant forms that do not respond to conventional medications. The researchers say AMPAR PET imaging could become a biomarker to predict which patients will benefit from ketamine therapy, potentially personalizing treatment for millions worldwide.